Fig 1: PRMT5 inhibition arrests TCR-induced cell cycle progression at the G1/S checkpoint. (A, B) mTh1 cells were activated on anti-CD3/CD28 coated plates, treated with 5 µM HLCL65 or vehicle control (DMSO) and harvested at the time of plating (resting) or 24, 48 or 72h post-plating. They were analyzed by immunoblot with PRMT5 (A) or H4R3 (B). Data plotted represent relative protein expression at indicated timepoints. Plots are combined 4-6 experiments, n=8-13/timepoint/condition. (C) mTh1 cells were plated on anti-CD3/CD28 coated plates, treated with vehicle (DMSO), 5 μMHLCL65 or 5 μM EPZ, and pulsed with tritiated 3H-thymidine at 24, 48 or 72h post-plating with vehicle or HLCL65. Cells were harvested 16-18h later. This is a representative experiment with 6 technical replicates/group, analyzed by two-way ANOVA with Tukey’s multiple comparisons test. (D) Supernatants from mTh1 cells plated on anti-CD3/CD28 coated plates were collected at 4h, 8h, 18h, 24h and 48h ± HLCL65, EPZ or vehicle and analyzed for IL-2 cytokine expression by ELISA. Data pooled from 3 independent experiments. Data analyzed by two-way ANOVA with Tukey’s multiple comparisons test. (E) Diagram of the cell cycle stages including Gap 1 (G1), Synthesis (S), Gap 2 (G2) and Mitosis (M). Cells represent the stage the cell is in at each phase of the cell cycle. Red lines on the cell cycle represent cell cycle checkpoints. Created with BioRender.com, modified from a template. (F) Flow cytometry plots of activated mTh1 cells demonstrating the gating strategy and representative results in the negative control (no BrdU), vehicle (DMSO) or PRMT5 inhibitor (2.5 µM HLCL65). (G) Quantification of the results from analyses in (F), corresponding to four independent experiments. Graphs for Gap 0/Gap 1 (G0/G1), Synthesis (S) and Gap 2/mitosis (G2/M). Results analyzed by paired t-test, n=7 pairs. Graphs are line or bar graphs representing mean ± SD with individual data points plotted (A–D) or before-after (plot individual points) (G). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Fig 2: Model of PRMT5 expression regulation after Th cell activation. (A) In naive T cells, NF-κB drives Prmt5 transcription and the NF-κB/mTOR/MYC axis drives PRMT5 protein induction through post-transcriptional and/or translational mechanisms. (B) In memory T cells, the NF-κB/mTOR/MYC axis drives PRMT5 protein induction through predominantly non-transcriptional mechanisms. Prmt5 transcription and miRNA loss may further contribute to PRMT5 induction via NF-κB/mTOR/MYC-independent mechanisms.
Fig 3: Ro blocks MSI2 mRNA binding and MSI2 binding specificity is PRMT5 independent.A Schematic illustration showing the MSI2 fusion to the ADAR catalytic domain. B HOMER motif enrichment was performed on ±100bp window flanking both sides of the edit site, totaling a 200 bp window per edit site. Top 5 motifs and the corresponding p-values are shown, statistical analysis by Fisher’s test. C Edit frequency on mRNAs in Z-138 cells overexpressing empty vector (MIG) or MSI2-ADAR and MSI2-ADAR treated with Ro for 24 h. Unpaired Kruskal–Wallis test; p-value < 0.0001. D Heatmap of MSI2 edit frequency in Z-138 cells treated with Ro, GSK-591, or the combination for 24 h. HyperTRIBE data was filtered to include MSI2-ADAR significant edit sites (adjusted p-value < 0.05, diff.frequency < = −0.1, fpkm > = 5) and MSI2-ADAR + Ro significant edit sites (adjusted p-value < 0.05, diff.frequency > = 0.1, fpkm > = 5). Only genes more significantly edited (beta-binomial test) are plotted. E Top significant enriched Oncogenic signatures in Ro-specific targets (1502 genes) using ENRICHR analysis Fisher exact test. F CDF plots showing the distribution of mRNA abundance changes in MSI2 HyperTRIBE targets (filtered by p-value < 0.05, diff.frequency < = −0.1, and fpkm > = 5) upon Ro treatment. A two-sided KS test was used to calculate p-value. Source data are provided as a Source data file.
Fig 4: PRMT5 is upregulated in human malignant melanoma tumors compared to normal epidermis, and subcellular localization of PRMT5 is heterogeneous amongst patient tumors.A, Brightfield image of PRMT5 staining in a Stage 2/3 tumor and its adjacent normal epidermis. PRMT5 protein was visualized with Vulcan FastRed label (pink); samples were counterstained with hematoxylin to delineate nuclei (arrows) and connective tissue (blue). B, malignant skin tumor of pathologic stage 4, showing predominantly nuclear PRMT5. C, malignant skin tumor of pathologic stage 4, showing predominantly cytoplasmic PRMT5 (arrows indicate hematoxylin-stained nuclei). D, representative images of PRMT5 staining in patient tumors of pathologic stages I–IV.
Fig 5: PRMT5, SDM and Cyclin E1 expression in CNS infiltrates correlate with RR EAE disease severity and/or progression. (A) Experimental design diagram: graphical representation of the typical EAE course in SJL mice injected with PLP(139-151). Created with BioRender.com. For actual EAE data in mice used for data in B through I, please see Figure S3 . (B) Mean scores calculated from mice injected with PBS instead of PLP (sham), mice collected at peak disease [day (D)14], in remission 1 (considered in remission if score dropped ≥1.5, D19-D25), in relapse (considered in relapse if score dropped by 1.5 or more and then rose by 1 or more, D28-33), in remission 2 (considered rem2 if mouse went through relapse and back to remission). (C) CNS infiltrating cells were collected at the times described in (B) and analyzed by immunoblot for PRMT5. (D–I) CNS infiltrating cell protein from individual mice or pooled from multiple mice (for conditions with low infiltrating CNS cell numbers) were used as samples for protein analyses of PRMT5, H4R3 and Cyclin E1 immunoblot and one aliquot was analyzed by flow cytometry for immune cell composition (and correlation analyses were performed. CNS infiltrating cell protein from individual mice or pooled from multiple mice (for conditions with low infiltrating CNS cell numbers) were used for protein analyses. A minimum of ~400,000 cells per sample were used and equal amounts of protein (5-15 μg) loaded and data were normalized to sham (C–I). (D, E) Spearman correlation of score vs. (D) PRMT5 or (E) H4R3 expression. (F, G) Pearson correlations were done between CD3+CD4+ T cell % and (F) PRMT5 or (G) H4R3 SDM expression in infiltrating CNS cells. (H, I) Correlation between Cyclin E1 expression and (H) PRMT5 expression or (I) score in infiltrating CNS cells. Pearson correlations were done for CD3+CD4+ T cells vs. protein expression or protein vs. protein. Spearman correlations were done for scores vs. protein expression. For (D–I), n=15-36 with technical replicates from n=59-83 total mice from 2-4 independent experiments. Graphs (B, C) quantify relative expression normalized to actin loading control and combined from 4 independent experiments, (9-18 sham, 13-16 peak, 21-35 rem1, 11-12 relapse, 4 rem2), biological samples were kept separate if possible, but pooled for each timepoint as necessary for each experiment, 1-2 technical replicates/experiment, graphs represent mean ± SD, *p < 0.05, ***p < 0.001, ****p < 0.0001.
Supplier Page from Abcam for Anti-PRMT5 antibody - C-terminal